Neoplasms, Unknown Primary Clinical Trial
Official title:
An Exploratory Cost-effectiveness Study of miRview™ Mets in Patients With Cancer of Unknown Primary (CUP) in Israel
The aim of the study is in cancer of unknown primary (CUP) patients, to compare the cost-effectiveness of miRview™ mets test with conventional work-up in identifying the primary tumor site.
Thousands of patients are diagnosed each year with metastatic cancer; however, about 3-5% of
them are diagnosed with Cancer of Unknown Primary (CUP). In order to identify the optimal
treatment plan for individual patients with CUP, the primary tumor site must be identified.
Patients undergo a wide range of costly, time-consuming, and inefficient tests to identify
the primary site of origin, often to no avail.
In this era of targeted therapies, the accurate diagnosis of the primary tumor can be
crucial. miRview™ mets is a new molecular diagnostic tool that identifies the
tissue-of-origin of metastatic tumors, with 90% sensitivity.
;
Observational Model: Case Control, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04025970 -
Molecular Analysis of Blood Samples in Standardized Cancer Care Referrals for SCAN and CUP
|
||
| Completed |
NCT00193609 -
Oxaliplatin and Capecitabine in the Treatment of Relapsed/Refractory Carcinoma of Unknown Primary Site
|
Phase 2 | |
| Completed |
NCT00193596 -
Gemcitabine/Irinotecan/ZD1839 vs Paclitaxel/Carboplatin/Etoposide/ZD1839 in Carcinoma of Unknown Primary Site
|
Phase 3 | |
| Completed |
NCT02628379 -
Outcomes of FoundationOne Directed Therapy in Cancer of Unknown Primary
|
||
| Completed |
NCT01540058 -
Trial Comparing a Strategy Based on Molecular Analysis to the Empiric Strategy in Patients With CUP
|
Phase 3 | |
| Not yet recruiting |
NCT00894569 -
Paclitaxel/Carboplatin With or Without Cetuximab in CUP
|
Phase 2 | |
| Completed |
NCT00193622 -
Bevacizumab and Erlotinib in the Treatment of Patients With Carcinoma of Unknown Primary Site
|
Phase 2 |